Related Experiment Video

Updated: Jul 4, 2025

Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

6.6K

Obesity in patients without diabetes undergoing coronary artery bypass graft surgery: Time to select patients for

Nick S R Lan1, Umar S Ali2, Robert Larbalestier3

  • 1Department of Cardiology, Fiona Stanley Hospital, 11 Robin Warren Drive, Murdoch, 6150 Perth, Western Australia, Australia; Harry Perkins Institute of Medical Research, The University of Western Australia, 5 Robin Warren Drive, Murdoch, 6150 Perth, Western Australia, Australia; Medical School, The University of Western Australia, 35 Stirling Highway, Crawley, 6009 Perth, Western Australia, Australia.

Obesity Research & Clinical Practice
|February 8, 2024
PubMed

Insights

Many patients need secondary prevention after coronary artery bypass graft (CABG) surgery. Over half of CABG patients without diabetes may benefit from semaglutide for cardiovascular risk reduction and weight management.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Coronary artery bypass graft (CABG) surgery patients require rigorous secondary prevention strategies.
  • The SELECT trial demonstrated semaglutide's efficacy in reducing cardiovascular events in overweight/obese patients with cardiovascular disease but without diabetes.
  • This study assessed the real-world eligibility of CABG patients for semaglutide therapy.

Discussion:

  • A significant proportion (53.3%) of 1386 non-diabetic CABG patients in an Australian hospital met SELECT trial criteria for semaglutide eligibility.
  • This highlights a substantial unmet need for advanced weight management and cardiovascular risk reduction in this high-risk surgical population.
  • The findings suggest semaglutide could be a valuable addition to secondary prevention protocols post-CABG.

Key Insights:

  • Over half of CABG patients without diabetes are potential candidates for semaglutide based on established criteria.
  • Semaglutide offers a potential therapeutic avenue for managing cardiovascular risk and obesity in post-CABG patients.
  • Real-world data supports the broad applicability of semaglutide in this vulnerable patient group.

Outlook:

  • Further research is needed to evaluate the clinical effectiveness and cost-effectiveness of semaglutide in the CABG population.
  • Clinical guidelines may need updating to incorporate semaglutide for secondary prevention in eligible CABG patients.
  • Investigating long-term outcomes and optimal integration into care pathways is crucial.

Keywords:
Cardiac surgical proceduresCardiovascular diseaseObesityOverweightWeight loss

More Related Videos

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice08:50

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice

Published on: October 18, 2024

573
Roux-en-Y Gastric Bypass Operation in Rats07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

23.5K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
322
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
201
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
263
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
173